The US FDA's complete response letter for Cempra Inc.'s community-acquired bacterial pneumonia (CABP) antibiotic Solithera (solithromycin) puts the company on a difficult and uncertain path forward.
The agency went against the recommendations of its advisory committee, apparently unwilling to wait until Phase IV to sort out...





